Adult Vaccine Market Size and Share Analysis (2025–2033) – A Renub Research Report
Executive Summary
The Global Adult Vaccine Market was valued at USD 21.77 Billion in 2024 and is projected to reach USD 37.18 Billion by 2033, growing at a CAGR of 6.13% from 2025 to 2033. Growth is largely driven by rising awareness of adult immunization, high disease prevalence, technological innovations in vaccine development, and an ageing global population.
Table of Contents
- Introduction
- Key Market Insights
- Market Drivers
- Market Challenges
- Segmental Analysis
- Influenza
- TdaP
- Meningococcal
- Hepatitis
- Regional Outlook
- United States
- Germany
- India
- Saudi Arabia
- Competitive Landscape
- Future Outlook
- Key Questions Answered
1. Introduction
Adult vaccines are designed for individuals aged 18 years and older to protect them from infectious diseases. These vaccines are critical in enhancing immunity, especially in elderly populations, healthcare workers, and individuals with chronic illnesses. Common vaccines include influenza, hepatitis A and B, HPV, shingles (herpes zoster), pneumococcal, and TdaP.
2. Key Market Insights
- Growing global demand post-COVID-19
- Emphasis on government immunization programs
- Innovations like mRNA and recombinant vaccines
- Expansion of adult vaccine access in emerging markets
Related Report
3. Market Drivers
A. Rising Geriatric Population & Immunosenescence
- By 2030, 1 in 6 individuals will be aged 60 or above.
- Immunosenescence increases vulnerability to infections.
- Vaccines like flu, shingles, and pneumococcal are vital.
B. Government Initiatives & Awareness Campaigns
- CDC’s Adult Immunization Schedule, WHO’s immunization agenda
- World Immunization Week (April)
- National Strategic Plans driving public acceptance
C. Technological Advancements
- Rise of mRNA, recombinant DNA, adjuvant-enhanced vaccines
- Multivalent and combination vaccines gaining traction
- Faster production cycles & extended shelf life
4. Market Challenges
A. Vaccine Hesitancy & Misinformation
- Social media-fueled myths impacting vaccine uptake
- Misconception that vaccines are only for children
B. Cost & Accessibility in LMICs
- Adult vaccines often excluded from subsidized programs
- Infrastructure limitations, cold chain challenges
5. Segmental Analysis
A. Influenza
- High seasonal flu incidence among elderly
- Quadivalent & high-dose vaccines popular
- Routine in North America, Europe, and APAC
B. TdaP
- Recommended every 10 years; during pregnancy
- High demand among healthcare workers, caregivers
- Integrated into occupational health policies
C. Meningococcal
- Mandated for college students, military recruits
- Targeted vaccination for travelers
- Expanded coverage for multiple serogroups
D. Hepatitis (A & B)
- High-risk groups include healthcare workers, drug users
- Part of many national immunization programs
- WHO-backed hepatitis elimination efforts
6. Regional Outlook
A. United States
- Strong infrastructure and insurance support
- CDC, Medicare, and private programs ensure access
- FDA recently approved Pfizer's ABRYSVO® RSV vaccine
B. Germany
- Universal health coverage drives high uptake
- Robert Koch Institute promotes adult vaccination
- Pfizer’s ABRYSVO vaccine approved EU-wide in April 2025
C. India
- Rising awareness, private sector healthcare investment
- Public-private partnerships improving vaccine literacy
- Pfizer & Artemis Hospital launched adult vaccination centers
D. Saudi Arabia
- Hajj-related vaccination programs (influenza, meningococcal, hepatitis)
- Vision 2030 reforms focus on preventive care
- Government-led initiatives supporting adult vaccination
7. Competitive Landscape
- Pfizer, GSK, Sanofi, Merck & Co., and Moderna dominate the market
- Focus on R&D, global outreach, and strategic partnerships
- New product launches like combination and RSV vaccines
8. Future Outlook
- Integration of adult vaccines in national programs globally
- Use of AI and big data to track immunization trends
- Expansion in Asia, Africa, and Latin America
- Rise of needle-free delivery systems & thermostable vaccines
9. Key Questions Answered
- What is the market size and growth rate of the global adult vaccine market?
- What are the key drivers boosting adult immunization rates?
- Which technological innovations are shaping adult vaccine development?
- How is vaccine hesitancy being addressed globally?
- Which adult vaccines hold the highest market share?
- How do government initiatives influence market expansion?
- What role does the ageing population play in vaccine demand?
- Which countries are leading in adult vaccine penetration?
- Who are the major players in the adult vaccine industry?
- What is the future forecast for adult vaccine accessibility and coverage?
Source: Renub Research
